DaVita price target raised to $73 from $63 at Piper Jaffray Piper Jaffray raised its price target for DaVita to $73 after CMS released its final dialysis rebasing rule. Piper expects shares of DaVita to trade higher as it believes the final rule will drive 2014 estimates higher and improve sentiment. The firm keeps an Overweight rating on the stock.
News For DVA From The Last 14 Days
Check below for free stories on DVA the last two weeks.